Tris Pharma Inc patents expiration
1. Dyanavel Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675703 | TRIS PHARMA INC | Modified release formulations containing drug - ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US10086087 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8597684 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8883217 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8062667 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(4 years from now) | |
| US11590228 | TRIS PHARMA INC | Extended release amphetamine compositions |
Sep, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 19, 2018 |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 19 October, 2015
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
DYANAVEL XR family patents
2. Dyanavel Xr 10 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US11590081 | TRIS PHARMA INC | Extended release amphetamine tablets |
Sep, 2038
(14 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 10 family patents
3. Dyanavel Xr 15 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US11590081 | TRIS PHARMA INC | Extended release amphetamine tablets |
Sep, 2038
(14 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 15 family patents
4. Dyanavel Xr 20 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US11590081 | TRIS PHARMA INC | Extended release amphetamine tablets |
Sep, 2038
(14 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 20 family patents
5. Dyanavel Xr 5 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US11590081 | TRIS PHARMA INC | Extended release amphetamine tablets |
Sep, 2038
(14 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 5 family patents
6. Tuzistra Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8790700 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8062667 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(4 years from now) | |
Drugs and Companies using CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX ingredient
Market Authorisation Date: 30 April, 2015
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
TUZISTRA XR family patents